Monitor for the actual 510(k) submission in Q1 2027 and any FDA acceptance or deficiency letter. The next material catalyst is the submission itself, which could trigger a binary outcome upon FDA decision.
Price Chart
Executive Summary
Conexeu Sciences provided a regulatory and manufacturing update for its lead wound care device candidate, Ten Minute Tissue™, confirming it remains on track for an FDA 510(k) submission in Q1 2027. The company reported that multiple scaled-up batches of CXU™ material met predefined specifications, supporting both regulatory testing and future commercial production. As a preclinical-stage company with no approved products, this update is a routine progress report with no material financial data or binary catalyst.
Key Facts
- Conexeu remains on track to submit an FDA 510(k) premarket notification for Ten Minute Tissue™ in Q1 2027.
- Multiple scaled-up batches of CXU™ material met predefined specifications for key material characteristics and product performance.
- The company is conducting manufacturing, preclinical, biocompatibility, chemical characterization, stability, and sterilization work in parallel.
- Conexeu has received FDA feedback through the Q-Submission process and is incorporating that advisory feedback.
- Ten Minute Tissue™ is an investigational device, not yet cleared or approved by the FDA.
Financial Impact
No financial figures disclosed; company is preclinical-stage with no revenue.
Risk Factors
- 510(k) submission may be delayed beyond Q1 2027 or not accepted by the FDA.
- FDA may request additional data or determine the device is not substantially equivalent to the predicate device.
- Preclinical results may not be predictive of clinical outcomes or regulatory clearance.
- Company may require additional capital to complete development and commercialization.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375490 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $2.96 | awaiting T+1 | — | $2.95 (+0.34%) |
Oct 20, 2026 7d ago | 8-K | $3.33 $3.30 | ▲ +0.90% | ▼ −0.28% | $2.95 (+11.41%) |
Oct 15, 2026 12d ago | Press Release | $3.06 $3.29 | ▲ +7.52% | ▲ +7.09% | $2.95 (−3.59%) |
Oct 6, 2026 21d ago | Press Release | $3.66 $3.64 | ▼ −0.55% | ▼ −0.31% | $2.95 (−19.40%) |
Jun 29, 2026 17w ago | 3 | $10.24 $10.92 | ▲ +6.64% | ▲ +5.86% | $2.95 (−71.19%) |
Jun 23, 2026 17w ago | Insider Buy | $10.69 $10.22 | ▼ −4.40% | ▼ −4.54% | $2.95 (−72.40%) |
Jun 3, 2026 20w ago | Press Release | $16.85 $16.00 | ▼ −5.04% | ▼ −5.44% | $2.95 (−82.49%) |
May 14, 2026 23w ago | Insider Cluster | — | awaiting T+1 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers